Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Niemann-Pick disease type C
Economic impact of diagnostic testing
5 evidence topics · 4 sources
Medicare payment for NPC1 and NPC2 gene sequencing, 2026
Medicare payment for exome and genome sequencing, 2026
Cost-effectiveness of plasma oxysterol screening in intellectually disabled patients in Canada
“Our objective is to compare costs and outcomes of plasma oxysterol screening versus current practice in diagnosis of NP-C disease among intellectually disabled (ID) patients using decision-analytic methods.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The outcomes of the base case model showed that using plasma oxysterol screening for diagnosis of NP-C disease among ID patients is a dominant strategy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average amount of cost saving was $3642 CAD and the incremental QALYs per each individual ID patient in oxysterol screening arm versus current practice of diagnosis NP-C was 0.0022 QALYs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Gene panel cost and test selection in the Australian standard of care
“Multigene panels are becoming more accessible and cost‐effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When gene panel tests are used, they should be symptom‐specific and must include the NPC1 and NPC2 genes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote